Shares of biotech company Gilead Sciences, which has been at the forefront of developing a treatment for COVID-19 patients, surged today after a report that a clinical trial for its antiviral drug, Remdesivir, was showing successful results by skleb1234
in its clinical trial of antiviral drug Remdesivir, which showed promising results in treating coronavirus.on Friday morning amid optimism that there could soon be a treatment for the virus.
The phase 3 trials, conducted by the University of Chicago Medicine, found that most patients treated with the drug had “rapid recoveries in fever and respiratory symptoms,” according to the original113 of the trial’s 125 patients had severe cases of coronavirus, but the large majority of people were discharged within a week after being given daily infusions of Remdesivir.
“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” Kathleen Mullane, the University of Chicago infectious disease specialist who is overseeing the study, according to STAT News.in overnight trading, with shares still up over 10% when the markets opened on Friday.Remdesivir was one of the first drugs to be identified as a possible treatment for coronavirus. Along with malaria drug hydroxychloroquine, it was one of two drugs that President Donald Trump called “very exciting.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead stock surges more than 10% on report of promising coronavirus treatmentGilead Sciences Inc. undefined shares rallied in the extended session Thursday following a report that one of the company's drugs showed promising results in...
Read more »
Stock market live updates: Rally losing steam, Gilead surges, Amazon dropsSeveral pharmaceutical and medical stocks like $ABT and $VRTX hit new highs today. Follow along with the latest stock market updates here:
Read more »
Dow rises over 500 points as investors pin hope on Gilead coronavirus treatment and U.S. reopeningStocks opened with strong gains Friday, putting equities on track to end a positive week on a strong note, after a treatment for the deadly COVID-19 pandemic...
Read more »
Why an analyst bullish on Gilead says antiviral drug ‘won’t solve’ COVID-19“Did remdesivir just ‘solve’ COVID? No,” says Umer Raffat, an analyst at Evercore ISI.
Read more »
Dow futures soar 800 points as investors pin hope on Gilead coronavirus treatment and U.S. reopeningStock-index futures Thursday night trade sharply higher, possibly setting the stage for a powerful rally for markets to end the week if the gains hold through tomorrow, amid progress toward a treatment for the deadly COVID-19 pandemic that has claimed more than 2 million lives world-wide.
Read more »
Gilead drug produced ‘rapid’ recovery in coronavirus patients, report saysGilead stock pops in after-hours trading; its experimental drug remdesivir is considered a front-runner in the race to develop a treatment for COVID-19 infections.
Read more »